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for some representatives uses. Two complementary expo-
sure assessments, human-biomonitoring and food-resi-
dues-monitoring, suggests that actual exposure levels are 
below these reference values and do not represent a public 
concern.
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Introduction
Glyphosate is the most widely used herbicide in the world. 
A broad spectrum herbicide, its uses include weed control 
in agriculture, vegetation control in non-agricultural areas, 
and harvesting aid as crop desiccant. Its use in agricul-
ture has increased considerably due to the development of 
glyphosate-resistant GM crop varieties; the herbicide has 
also been used to control illegal crops through massive 
aerial applications (Solomon et al. 2007). The widespread 
use and public debate regarding these uses have aroused 
societal concern and a scientific controversy on the toxic-
ity of glyphosate (Faria 2015) beyond the scientific debate 
(Blaylock 2015).
Glyphosate was considered an advantageous herbicide 
until its use led to the evolution of glyphosate-resistant 
weeds (Duke and Powles 2008) and studies suggest-
ing effects of glyphosate-based formulations in humans 
and wildlife were published. Interest in glyphosate has 
increased exponentially among scientists, and the subject 
accounted for 5% of the articles on pesticides included 
in PubMed during 2015. About 25% of the articles cover 
the toxicity endpoints in humans and all types of organ-
isms, and the majority is conducted with glyphosate-
based formulations, containing other ingredients. Some 
Abstract Glyphosate is the most widely used herbicide 
worldwide. It is a broad spectrum herbicide and its agri-
cultural uses increased considerably after the development 
of glyphosate-resistant genetically modified (GM) varie-
ties. Since glyphosate was introduced in 1974, all regu-
latory assessments have established that glyphosate has 
low hazard potential to mammals, however, the Interna-
tional Agency for Research on Cancer (IARC) concluded 
in March 2015 that it is probably carcinogenic. The IARC 
conclusion was not confirmed by the EU assessment or the 
recent joint WHO/FAO evaluation, both using additional 
evidence. Glyphosate is not the first topic of disagreement 
between IARC and regulatory evaluations, but has received 
greater attention. This review presents the scientific basis 
of the glyphosate health assessment conducted within the 
European Union (EU) renewal process, and explains the 
differences in the carcinogenicity assessment with IARC. 
Use of different data sets, particularly on long-term toxic-
ity/carcinogenicity in rodents, could partially explain the 
divergent views; but methodological differences in the 
evaluation of the available evidence have been identified. 
The EU assessment did not identify a carcinogenicity haz-
ard, revised the toxicological profile proposing new toxico-
logical reference values, and conducted a risk assessment 
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ingredients may be more toxic than glyphosate for non-
plant species (Kim et  al. 2013; Mesnage et  al. 2013; 
Nobels et  al. 2011), ingredients classified as carcino-
genic or mutagenic are not expected to be used and must 
be indicated in the label, however, the full composition 
of the formulation is not disclosed by the manufacturers, 
therefore, it is impossible for researchers to apply mix-
ture toxicity methods and attribute toxicity to specific 
ingredients.
The risk assessment of a pesticide for human health 
integrates two aspects. First, the hazard identification clari-
fies the toxicological profile of the substance, setting the 
type of health effects it is expected to produce in humans 
depending on the level of exposure, triggering the hazard 
classification and setting the toxicological reference values 
to be used in the risk assessment. Then, for each intended 
use, the expected level of exposure is calculated and com-
pared with the reference values. While the hazard potential 
is intrinsic and, therefore, expected to be equivalent in all 
evaluations, the risk is related to the use of the substance—
which is defined as the likelihood and magnitude of adverse 
effects—and strongly depends on the patterns and condi-
tions of use.
Glyphosate has been the subject of regular assess-
ments by national and international regulatory agencies 
(JMPR 2006; Williams et  al. 2000). All had established 
that glyphosate has a relatively low toxicity in mammals. 
However, a recent report from the International Agency for 
Research on Cancer (IARC) concluded that the herbicide 
and its formulated products are probably carcinogenic in 
humans (Guyton et al. 2015a, b; IARC 2015). The aim of 
IARC’s assessments is to identify carcinogenicity hazards 
as a first step in carcinogenic risk assessment. IARC assess-
ments do not include recommendations regarding regula-
tory or legislative decisions; they are scientific evaluations 
informing regulatory assessments. Consequently, the IARC 
conclusion triggered a reconsideration of the evidence on 
carcinogenicity in the EU evaluation, and more recently by 
the Joint FAO/WHO Meeting on Pesticide Residues. The 
European Union renewal process (European Food Safety 
Authority 2015a, b; Germany 2015) was the first compre-
hensive regulatory assessment of glyphosate conducted 
after the IARC evaluation. Following a detailed assess-
ment of all available information, the European assessment 
reached a different conclusion, increasing the scientific and 
social debate. In 2016 the Joint FAO/WHO Meeting on 
Pesticide Residues concluded that glyphosate is not carci-
nogenic in rats but could not exclude the possibility that it 
is carcinogenic in mice at very high doses, this information 
was used in the risk assessment concluding that glypho-
sate is unlikely to pose a carcinogenic risk to humans from 
exposure through the diet (JMPR 2016). This manuscript 
explores possible reasons for the different conclusions, with 
a focus on the EU assessment, as this is the evaluation in 
which the authors have been involved.
Typically, regulatory assessments come to conclusions 
similar to those of IARC, but there are exceptions (Pearce 
et al. 2015). Scientific divergences may result from differ-
ent sets of evidence, different approaches and methods, or 
different interpretations when weighing ambiguous results. 
Divergences are particularly likely when one evaluation 
includes additional evidence. In this context, it is important 
to mention that the EU evaluation, which considered stud-
ies not available to IARC, also updated the toxicological 
profile of glyphosate, proposing new toxicological refer-
ence values.
IARC monographs cover carcinogenicity hazard identifi-
cation. When statistical associations between exposure and 
cancer incidences are observed in epidemiological studies, 
the assessment of causal relationships may lead to divergent 
conclusions (Rhomberg 2015a, b). The comparison of both 
glyphosate assessments is used below to explain the differ-
ent aims, methods and possible divergences between regu-
latory and IARC assessments—focusing on the glyphosate 
carcinogenicity hazard identification as a case study—and, 
more importantly, their role in the assessment of risks to 
consumers and public health concerns. The example is par-
ticularly useful as both evaluations were conducted within 
the same period, and as the EU assessment, based on the 
United Nations Globally Harmonised System (UN-GHS) 
for classification of chemicals, is also relevant in the broad 
international context.
Methodology: scientific assessment 
of carcinogenicity and its use in the regulatory 
context
Pesticides are heavily regulated chemicals and require pre-
marketing authorisation in most jurisdictions. The EU sys-
tem also includes a renewal process, requiring all pesticides 
to be regularly re-assessed in the light of new scientific 
developments and information requirements. The EFSA 
assessment (European Food Safety Authority 2015b) fol-
lowed an evaluation carried out by the European Commis-
sion in 2002.
The identification of carcinogenic chemicals and carcin-
ogens in food is of high societal and scientific interest (Bar-
low and Schlatter 2010). The communication of the out-
come of the risk assessment is complex and controversial 
in the case of equivocal results (Downes and Foster 2015). 
The identification of a mutagenic or genotoxic mechanism 
plays an important role in risk assessment and requires a 
critical evaluation of the data as well as expert judgment 
(Eastmond 2012). The hazard assessment is linked to the 
classification; the EU uses the hazard assessment system 
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for chemicals developed by the United Nations following 
the 1992 UN Earth Summit (Pratt 2002). This Globally 
Harmonised System for classifying chemicals replaces pre-
vious national and international approaches, is specifically 
recommended by FAO to be used for pesticides, and is 
implemented in the EU Classification, labelling and pack-
aging (CLP) regulation—(EC) No 1272/2008—and other 
jurisdictions (UNECE http://www.unece.org/trans/danger/
publi/ghs/implementation_e.html).
IARC and regulatory assessments are usually comple-
mentary. The different roles, methods and information 
sources of IARC and regulatory assessments, as well as 
the implications for public health, must be considered in 
case of divergences and are summarised in Table 1. IARC 
identifies carcinogenic hazards resulting from occupational, 
environmental, and lifestyle exposures and agents as a first 
step of the risk assessment process, and has developed an 
internationally recognised grouping system that includes 
defined criteria and methodology (Guyton et  al. 2015a, 
b; Lauby-Secretan et  al. 2016; Pearce et  al. 2015; Straif 
et  al. 2014). The recently developed approach for assess-
ing mechanistic information, based on the characteristics 
of IARC group 1 carcinogens, was applied for glyphosate 
(Smith et al. 2016). Regarding data sources, IARC assess-
ments are primarily based on published evidence, i.e. sci-
entific publications and regulatory assessments; industry-
sponsored studies are used when reviewed and reported 
in regulatory evaluations, becoming a relevant secondary 
source for regulated agents such as pesticides. Both, scien-
tific publications and mandatory industry-sponsored stud-
ies, were primary sources in the EU evaluation.
For pesticides, IARC identifies the “carcinogenic 
agent” as the active pesticide substance and its commercial 
formulations; the specific role of the other formulation 
ingredients in the occurrence of effects is not considered 
separately from the active ingredients. This is in line with 
the role of human evidence in IARC assessments. Epide-
miological studies of farmers and consumers have very 
limited information on actual exposure levels (Ntzani et al. 
2013), and use the pesticide active substance as descriptor, 
combining individuals exposed to different formulations 
without discriminating the different compositions. In the 
regulatory context, each formulation should be assessed 
according to its composition, identifying the role of the 
active substance and of the other ingredients; and the risk 
management measures are set for the chemical responsible 
for the effect, either active substance or co-formulant.
The UN-GHS and IARC frameworks use different ter-
minology, but the definitions for sufficient and limited evi-
dence in humans and in animals are similar and can be used 
to establish equivalences between both schemes, as pre-
sented in Table 2.
This approach allows a comparison of the pesticides 
evaluated by IARC with the current EU classification 
(Table  3 and supplementary material Annex 1). The EU 
classification includes scientific assessments conducted by 
the European Chemicals Bureau of the European Commis-
sion—some, but not all, based on EFSA evaluations—and 
by the Committee for Risk Assessment of the European 
Chemicals Agency.
A total of 53 pesticides have been assessed under both 
systems. For about half—29 out of 53—the classifications 
are equivalent; the EU classification is more severe/con-
servative for 14 pesticides and less severe/conservative for 
11. It should be noted that 8 out of the 11 pesticides with 
more severe/conservative classification by IARC are those 
Table 1  Comparison of IARC and regulatory assessments roles and methodological elements
Issue IARC EU regulatory assessment
Role Hazard based identification. First step to be used by authorities 
in their risk assessments. No regulatory power
Scientific assessment covering hazard identification (classifica-
tion), hazard characterisation (setting toxicological reference 
values), exposure assessment, and risk characterisation
Formal support for decision making
Coverage IARC selection, based on criteria such as identified concern or 
human exposure. Chemical, physical, biological or behav-
ioural “agents”
58 pesticides
Mandatory, 1355 pesticide active substances in the EU data 
base. Chemical and microbial pesticides
Method IARC developed methodology, described in the “preamble”. 
Applicable to all agents
For chemical pesticides, hazard identification based on UN GHS 
criteria
Detailed guidance from ECHA available
Sources Review of published information. Summaries of industry 
sponsored studies used as secondary source if obtained from 
regulatory agency reports
Full set of mandatory (OECD guidelines) GLP studies and 
epidemiological data
Review of scientific peer-review publications, last 10 years
Information collected through a public consultation
Formulations “Agent” grouped as active substance and all formulated prod-
ucts together
UN GHS principles applied to the active and then to each for-
mulation, accounting for all other ingredients
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assessed in recent IARC monographs. New substances 
are evaluated and others re-evaluated regularly, leading to 
changes in the classification; thus the table represents just 
a “screen-shot” of two rolling processes. Differences with 
IARC and between jurisdictions have also been reported 
for other regulatory assessments (Choi and Lim 2010). 
Both IARC and regulatory classifications are based on the 
information available at the time of the evaluation. For pes-
ticides, the identification of possible concerns triggers the 
generation of additional evidence and a subsequent evalu-
ation; consequently, some differences are not real scientific 
divergences but the result of expert re-evaluations based on 
different sources of evidence. This may have played a role 
in the case of glyphosate, as discussed below.
Discussion
Understanding the divergence: glyphosate 
carcinogenicity assessment
The carcinogenicity of glyphosate has been reviewed by 
several national and international agencies (Ibrahim 2015). 
The outcome of the EU assessment, the differences with 
the IARC evaluation (IARC 2015), and the authors’ views 
explaining these differences, are summarised below. Addi-
tional details are provided in the supporting information.
Human evidence
IARC (2015) offered the most up-to-date review of human 
epidemiological studies on glyphosate. Positive evidence 
regarding an association between exposure to glyphosate 
and non-Hodgkin lymphoma, observed in some case-con-
trol studies but not confirmed by cohort studies, was con-
sidered sufficient by IARC to conclude on “limited evi-
dence” in humans. Limited evidence is defined as a positive 
association observed between exposure to the agent and 
cancer, for which a causal interpretation is considered to 
be credible, but chance, bias or confounding could not be 
ruled out with reasonable confidence. This definition was 
developed by IARC and introduced in the UN-GHS cri-
teria (United Nations 2003) and EU Regulation (EC) No 
1272/2008. EFSA re-assessed the same information; the 
association with non-Hodgkin lymphoma was discussed 
during an expert meeting. The statistically significant asso-
ciation was considered limited due to low power, lack of 
consistency, and the view that greater weight should be 
given to the cohort study for non-rare tumours. Consider-
ing causality, the majority of the experts concluded that the 
epidemiological evidence was very limited, and insufficient 
for classification. Although the role of the weight attributed 
to case–control studies versus cohort studies cannot be fully 
ruled out, the main reason for the divergent views could 
be the possibility of bias, chance results and confounding 
effects, as IARC concluded that the limited evidence in 
humans was supported by sufficient evidence of carcino-
genic potential in animals and strong mechanistic evidence 
for genotoxicity and oxidative stress. As explained below, 
the EU evaluation used additional evidence regarding ani-
mal carcinogenicity and genotoxicity, and reached different 
conclusions.
Carcinogenicity in animals
Information sources There is only one published study 
on the carcinogenicity of the active substance glyphosate in 
rats (Chruscielska et al. 2000), which showed no significant 
increase in tumour incidences in any treated group. Two 
additional published studies on glyphosate formulations, the 
first one on initiation-promotion in mice (George et al. 2010) 
and the second one, a study of rats (Seralini et  al. 2014) 
that was retracted and republished creating some contro-
versies (Fagan et al. 2015), were considered inadequate by 
IARC and EFSA for carcinogenicity assessment (European 
Food Safety Authority 2012; IARC 2015). Consequently, 
industry-sponsored studies, required by several jurisdic-
tions worldwide, have constituted the basis for the assess-
ment of animal carcinogenicity by both IARC and EFSA. 
As expected for a regulatory assessment, EFSA assessed the 
original study reports. According to their principles, IARC 
used unpublished studies based on secondary sources, i.e. 
the information on the studies as published by JMPR (2004) 
and US-EPA (1993). The time difference, over a decade, 
between the IARC monograph and the published regula-
tory assessments must be considered. Five new studies, not 
assessed by the JMPR and US-EPA, and therefore, not con-
sidered by IARC, were considered valid and included in the 
Table 3  Overall comparison of the carcinogenicity assessments of pesticides conducted by EFSA and IARC (see supplementary material for 
information on the pesticides classified in each category)
Category 1A Category 1B Category 2 No classification Not assessed/no 
data
EU 0 17 53 30 4
Group 1 Group 2A Group 2B Group 3 Group 4 Not assessed
IARC 3 8 13 34 0 56
 Arch Toxicol
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EU assessment. The IARC assessment is based on the re-
assessment of industry-sponsored studies, two in mice and 
four studies in rats, plus the negative published study in rats. 
The EU assessment included five additional valid studies, 
two in mice and three in rats; one mouse study was excluded 
due to a likely viral infection in the experimental population 
and one rat study was considered inadequate due to study 
deficiencies. Table 4 summarises the studies used in the EU 
assessment; additional information is provided in Table S-2 
as supplementary material, with links to the detailed sum-
maries for each study and its assessment as published in the 
EFSA background document (Germany 2015). Additional 
information and raw data have been published as supple-
mentary information in a recent industry-sponsored review 
of glyphosate carcinogenicity (Greim et al. 2015).
Assessment of the available evidence In its weight of evi-
dence, the IARC Working Group considered a statistically 
significant trend for renal tumours in male mice in one study 
(study A in Tables 4, 5) and for haemangiosarcoma in the 
other (study B in Tables  4, 5). No statistically significant 
increase in tumour incidence in females was observed in 
these studies. In the weight of evidence in rats, the IARC 
Working Group considered increases in the incidence of 
adenomas, with no evidence of progression to carcinomas, 
in pancreatic islet cells in males (studies E and F in Table 4), 
hepatic cells in males (study E in Table 4) and thyroid C-cell 
in females (study E in Table 4). No increase in tumour inci-
dence was observed in three studies (studies G, K and M in 
Table  4). The EU assessment followed the weight of evi-
dence approach required by the UN-GHS criteria (United 
Nations 2015) and further clarified in the ECHA guidance 
(European Chemicals Agency 2015). The statistical signifi-
cance found in trend analysis in some studies was balanced 
against the lack of statistical significance in pair-wise com-
parison tests, lack of consistency in multiple animal studies, 
slightly increased incidences only at dose levels at or above 
the Maximum Tolerable Dose (MTD), lack of pre-neoplas-
tic lesions and/or whether the studies fell within the relevant 
historical control range. A specific comparison of tumour 
incidences in male CD-1 mice from four carcinogenicity 
studies (no change in tumour incidence was observed in 
females) is provided in Table 5, and the detailed scientific 
assessment and weight of evidence for each tumour type is 
summarised in Table 6.
Comparison of  both  weight of  evidence approaches As 
indicated by Portier et al. (Portier et al. 2014), individual sci-
entific studies are rarely, if ever, conclusive. In our view, this 
is particularly relevant when assessing the carcinogenicity 
potential in humans using animal studies, and supports the 
need for a consistency check combining all available studies 
as mandated in the UN-GHS criteria.
In the absence of conclusive human evidence, and 
despite some views suggesting the need for re-assessing 
its relevance (Beyer et  al. 2011; Marone et  al. 2014; Osi-
mitz et al. 2013), rodent long-term toxicity/carcinogenicity 
studies are used for predicting carcinogenicity in humans 
(Doktorova et al. 2012). False positives and false negatives 
should both be considered, weighing the evidence (Lutter 
et  al. 2015; Rhomberg 2015a, b; Rhomberg et  al. 2013) 
and assessing specifically human relevance; and linked to 
the MTD concept, the relevance of toxicity-induced carci-
nogenic effects observed in experimental animals only at 
very high doses. The UN-GHS, and therefore, the EU CLP 
approach are based on UN harmonised criteria for weigh-
ing the evidence from rodent studies. Regulatory (European 
Chemicals Agency 2015) and non-regulatory (McGregor 
et al. 2010) guidance is available for weighing the evidence 
in line with the UN-GHS criteria. Table 7 summarises the 
assessment of the different UN-GHS Weight of Evidence 
elements in the EU assessment, and includes a comparison 
with the weight provided in the IARC evaluation. It should 
be noted that the authors of this paper did not participate in 
the IARC assessment, and therefore, the IARC columns are 
based on the information extracted from the IARC pream-
ble and monograph, and do not reflect the Working Group 
discussions except when specifically reported in the mono-
graph. The elements detailed in Tables 5, 6 and 7, and used 
in the EU evaluation, are not only specific components of 
the regulatory guidance (European Chemicals Agency 
2015), but, as described below, are also fully supported by 
current scientific knowledge on the assessment of animal 
studies.
Due to the large number of studies, the assessment of 
chance results is particularly relevant. Dose–response 
within the study, consistency among similar studies, 
consistency or justified differences between sexes, and 
comparison with historical controls, are considered key 
elements for identifying chance effects. The Bradford 
Hill guidelines published in 1965 are still considered 
a reference for assessing causality (Wakeford 2015), 
and have been included in the IPCS framework and its 
respective updates (Boobis et al. 2006, 2008; Meek et al. 
2014a; Sonich-Mullin et  al. 2001). Although the frame-
work focuses on the relevance of the mode of action, 
dose–response relationships and consistency among stud-
ies are also indicated as key elements. The statistical 
assessment is the first step for assessing the results of the 
toxicity tests, and has received significant attention from 
both, regulatory bodies (e.g. OECD guidelines on testing 
and assessments of chemicals) and academics (Hothorn 
2014); nevertheless, the statistical analysis should be con-
sidered part of an overall assessment. This is particularly 
relevant in cases such as glyphosate, where the statistical 
analysis is inconsistent or inconclusive, with significant 
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differences in the trend, but not in the pair-wise analysis. 
Lack of consistency at similar doses in the same species 
and strain and lack of dose–response relationships can be 
observed for malignant lymphomas in mice (Tables 5, 6) 
and adenomas in rat (Table  6). Kobayashi et  al. (2010) 
reviewed the grounds for considering statistically signifi-
cant changes as incidental, observing similar trends for 
unpublished and peer-reviewed scientific publications. 
Lack of dose–response is reported as the main justifica-
tion for disregarding the results as incidental, followed 
by lack of physiological/toxicological significance of the 
effects and the comparison with historical controls. These 
studies support the concern surrounding conclusions that 
are based only on statistical significance of increased 
tumour incidences in a particular study, without consid-
erations of the biological relevance of the finding.
Although the concurrent control group is always the 
most relevant comparator, the use of historical control data, 
also in combination with background incidental lesions 
(McInnes and Scudamore 2014), can be essential in cases 
of equivocal results to detect both, false positive and false 
negative situations. In addition to best practices (Greim 
et  al. 2003; Keenan et  al. 2009), graphical visualisations 
(Elmore and Peddada 2009) and statistical approaches 
(Dinse and Peddada 2011; Peddada et al. 2007) have been 
developed, although direct comparison with the historical 
control range in the test laboratory around the time of the 
study is the approach mostly used in the regulatory context, 
and preferred in the EU assessment. This approach was 
considered for malignant lymphomas and haemangiosarco-
mas in mice when the studies reported the historical range 
for the test laboratory.
Excessive toxicity, for instance toxicity at doses exceed-
ing the MTD, can cause effects such as cell death (necro-
sis) with associated regenerative hyperplasia, which in 
turn can lead to tumour development as a secondary effect, 
unrelated to the intrinsic potential of the substance itself 
to cause tumours at lower and less toxic doses (European 
Chemicals Agency 2015; Knight et  al. 2006). Also in the 
assessment of cell proliferation as mode of action for non-
genotoxic carcinogens, systemic toxicity and overt cyto-
toxicity in the target tissue should be avoided (Wood et al. 
2015). It has been suggested that almost all chemicals, 
including those non-genotoxic and without structural alerts 
for carcinogenicity, would produce statistically significant 
trends if tested at or above the MTD in a sufficiently large 
number of animals (Gaylor 2005). Significant trends for 
tumour induction were observed in two mouse studies but 
only at very high doses, well above the proposed top dose 
for carcinogenicity studies (OECD 2012) of 1000  mg/kg 
bw per day; clear indications of toxicity were observed at 
these high doses, such as reduced body weight, histopatho-
logical changes in the bladder and liver, and other toxic Ta
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signs; consequently, the tumour induction trends were con-
sidered confounding effects due to excessive toxicity.
Mechanistic assessment
The relevance of the mode of action for humans constitutes 
the basis of the IPCS framework (Boobis et al. 2006, 2008; 
Meek et  al. 2014a; Sonich-Mullin et  al. 2001). Mode of 
action is defined as a biologically plausible series of key 
events leading to an effect (Sonich-Mullin et al. 2001) and 
involves interdependent networks of events with feedback 
loops. Differences in networks between and within human 
and animal populations account, in part, for interspecies 
differences and human variability (Meek et al. 2014a). Cur-
rent approaches explore the applicability of the Adverse 
Outcome Pathway approach (Collier et  al. 2016; Edwards 
et  al. 2016; Zhou 2015) as a framework for linking the 
initial molecular interactions with the tumour promotion 
though plausible key events (Becker et  al. 2015; Downes 
and Foster 2015). As the EU evaluation concluded that the 
incidences were due to chance and bias and the evidence 
does not indicate that glyphosate is an animal carcino-
gen, no further assessment of relevance for humans was 
required.
IARC, with a different focus, not targeted to individ-
ual chemicals but to a broad range of agents, has recently 
developed a new weight of evidence scheme, by extracting 
the “key characteristics” from the physical/chemical/bio-
logical/behavioural agents classified by IARC in category 
1 (Smith et al. 2016). These key characteristics are defined 
as common properties, not to be considered mechanisms 
of Adverse Outcome Pathways, although are postulated as 
a method to synthesize information and develop adverse 
outcome networks. The ten characteristics are the abilities 
of an agent to: (1) act as an electrophile either directly or 
after metabolic activation; (2) be genotoxic; (3) alter DNA 
Table 6  Summary of the weight of evidence of the EU assessment for the different tumour types
Tumour type/species Significant trends Weight of evidence in EU assessment
Renal tumours, mice 2 out of 4 studies
TOX9552381
(6% combined adenomas and carcinomas in males 
at 4841 mg/kg bw day)
ASB2012-11493
(4% adenomas in males at 4348 mg/kg bw day)
Both studies, trends observed only at high dose 
(>4000 mg/kg bw per day), where general toxicity 
(such as reduced bw, histopathological findings in 
liver, and bladder in one study and reduced bw gain, 
severe gastro-intestinal effects in the other) may be 
confounding factors
No statistical significance in a pair-wise comparison
One trend in one study did not consider the higher 
survival at the top dose
Malignant lymphomas, mice 2 out of 4 studies
ASB2012-11493
(12% males at 4348 mg/kg bw day)
ASB2012-11492
(10% males at 810 mg/kg bw day)
Malignant lymphomas is one of the most common 
neoplasms in CD-1 mice, females being more prone 
to this tumour type than males
No statistical significance in a pair-wise comparison
First study within historical controls and trend 
observed only at high dose (>4000 mg/kg bw per 
day), where general toxicity may be a confounding 
factor
Second study inconsistency in results among 4 stud-
ies comparing similar dose levels
Haemangiosarcomas, mice 2 out of 4 studies
TOX9552382
(8% males at 1000 mg/kg bw day)
ASB2012-11493
(4% males at 4348 mg/kg bw day)
No statistical significance in a pair-wise comparison
First study within historical control range
Second study trend observed only at high dose 
(>4000 mg/kg bw per day) where general toxicity 
may be a confounding factor
Hepatocellular adenomas, rats 1 out of 8 studies
TOX9300244
(15% males at 940 mg/kg bw day)
No statistical significance in a pair-wise comparison
Marginal trends in benign tumours limited to one sex, 
not reproduced among 8 long term studies (3 stud-
ies in SD rats and 5 studies in Wistar rats)
Thyroid C-cell adenomas, rats 1 out of 8 studies
TOX9300244
(10% females at 457 and 1183 mg/kg bw day)
No statistical significance in a pair-wise comparison
Marginal trends in benign tumours limited to one sex, 
not reproduced among 8 long term studies (3 stud-
ies in SD rats and 5 studies in Wistar rats)
Pancreatic islet cell adenomas, rats Incidences without dose response trends in 2 out of 
8 studies
Lack of dose–response does not support an effect 
related to glyphosate administration
All other tumours, mice and rats No increased incidences observed in 4 mice and 8 
rat studies
No observed incidences in a large number of valid 
studies
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repair or cause genomic instability; (4) induce epigenetic 
alterations; (5) induce oxidative stress; (6) induce chronic 
inflammation; (7) be immunosuppressive; (8) modulate 
receptor-mediated effects; (9) cause immortalization; and 
(10) alter cell proliferation, cell death, or nutrient supply. It 
should be noted that this new approach has been applied to 
the recent IARC monographs, including the assessment of 
glyphosate.
Genotoxicity
The EU evaluation considers in vitro genotoxicity tests and 
in vivo studies performed in mammals, as those are con-
sidered to be more relevant for the assessment of the risk 
to humans (Yauk et  al. 2015). Sixteen in vivo studies in 
somatic cells and two in vivo studies on germ cells were 
reported on rodents orally treated with dose levels up to 
5000 mg/kg bw, or via intraperitoneal injections. All stud-
ies were conducted according to internationally validated 
guidelines; some non-GLP published studies gave negative 
results, while two non-GLP studies were positive in mice 
treated intraperitoneally with dose levels in the range of the 
intraperitoneal  LD50 for mice, one study presenting major 
flaws. No genotoxic effects on germ cells were detected in 
rats or mice treated orally at dose levels up to 2000 mg/kg 
bw. The induction of DNA strand breaks observed in mice 
treated intraperitoneally with doses close to or in excess 
of the  LD50 has been associated to secondary effects of 
cytotoxicity (JMPR 2006; Kier 2015). Modes of action 
associated with secondary cytotoxicity should be excluded 
from the assessment of the intrinsic genotoxicity potential 
(Bryce et al. 2014; Kitamoto et al. 2015).
IARC combines information on glyphosate and glypho-
sate-based formulations, compiling studies on humans, 
other mammals, other vertebrates, invertebrates, and plants. 
Regarding in vivo mammalian studies, IARC reports posi-
tive effects for 5 out of 11 studies; four negative studies 
on micronucleus formation and dominant lethal mutation 
reported by JMPR (2006) are not included in the IARC 
evaluation. Positive effects are described only for intraperi-
toneal administrations at doses of 300 mg/kg bw. Although 
these effects had been previously postulated as secondary 
to (cyto)toxicity (Heydens et  al. 2008; JMPR 2006), the 
role of (cyto)toxicity is not discussed in the IARC mono-
graph. Positive effects are mostly observed in the liver, 
an organ that is considered inappropriate for assessing in 
vivo genotoxic effects after intraperitoneal administration 
(JMPR 2006).
A recent meta-analysis on micronuclei frequency (Ghisi 
et al. 2016) has confirmed that positive effects are limited 
to intraperitoneal administrations, and that the response is 
much higher for glyphosate-based formulations than for 
the active substance. Cytotoxicity of the surfactants added Ta
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to the formulations is presented as a plausible explana-
tion, while the cytotoxicity of glyphosate in intraperitoneal 
administrations at high doses is not discussed. Significant 
differences are observed for males but not for females, a 
general difference is reported in the comparison of mam-
malian and non-mammalian systems, although similar 
responses are observed for mice and crocodilians (Ghisi 
et al. 2016).
Non‑genotoxic modes of action
Non-genotoxic modes of action for carcinogenicity are 
assumed for about 9% of IARC classifications (Hernandez 
et al. 2009) and include endocrine disruption, tumour pro-
motion, tissue-specific toxicity and inflammation, cytotox-
icity and immune suppression, inhibition of gap-junction 
intercellular communications (GJICs), and other mecha-
nisms (Benigni et al. 2013; Hernandez et al. 2009).
In the EU evaluation, the lack of evidence for carcino-
genic potential of glyphosate meant that no further thought 
regarding the mode of action was considered necessary. 
IARC assessed the “key characteristics of human carcino-
gens” (Smith et  al. 2016), concluding that there is weak 
evidence for receptor-mediated effects, cell proliferation or 
death, and immune effects, and strong evidence of oxida-
tive stress.
Role of surfactants and other co‑formulants
The EU assessment focuses on glyphosate, aiming to estab-
lish the properties of the active substance to be considered 
in the assessment of each formulation by individual Mem-
ber States. IARC has a different approach, addressing both 
glyphosate and its formulations. The potential role of the 
co-formulants, which differ among formulations, is not 
assessed; however, the IARC monograph reports a large 
number of mechanistic studies with negative results for 
glyphosate but positive results for glyphosate-based formu-
lations, as well as differences between formulations con-
taining similar concentrations of glyphosate, indicating that 
other ingredients could lead to the effects observed when 
testing formulations (Coalova et al. 2014; Cox and Surgan 
2006). Similar results are observed for other pesticides and 
particularly for herbicides (Cavas 2011); this is not surpris-
ing, as the mode of action leading the herbicidal activity is 
usually not linked to the toxicological profile in mammals.
Surfactants are frequently used in herbicide formula-
tions, including glyphosate. Polyethoxylated tallowa-
mines are several orders of magnitude more cytotoxic than 
glyphosate (Mesnage et al. 2013); the mode of action is cell 
death with inhibition of the mitochondrial succinate dehy-
drogenase activity and membrane damage leading to necro-
sis. This mode of action is different from glyphosate, while 
similar to that observed for glyphosate-based formulations 
(Benachour and Seralini 2009). These tallowamines also 
produce oxidative and DNA damage (Nobels et al. 2011), 
and increase the apoptotic potential of glyphosate (Kim 
et  al. 2013). Other surfactants as well as solvents used in 
pesticides formulations are cytotoxic and, possibly, geno-
toxic (Nobels et al. 2011).
The cytotoxicity and potential genotoxicity of other 
ingredients should be considered before assuming that the 
effects observed for a formulated product are linked to the 
active substance. Secondary genotoxic effects produced by 
cytotoxicity should also be distinguished from true geno-
toxic potential (Bryce et  al. 2014; Kitamoto et  al. 2015). 
In fact, the UN and EU guidance recommends carcino-
genicity and genotoxicity studies to be conducted on indi-
vidual chemicals, limiting testing of mixtures/formulations 
to cases where synergistic effects are expected (United 
Nations 2015).
From hazard assessment to public health risk 
assessment
While IARC focuses exclusively on the hazard identifica-
tion, regulatory assessments also include the estimation of 
the toxicological potency of the substance and the setting 
of toxicological reference values to be used in the human 
health risk assessment. The toxicological reference values 
offer quantitative indications of the toxicity of a chemical, 
indicating the levels of human exposure that, according to 
the current scientific knowledge, are considered acceptable 
from a regulatory perspective. The recent EFSA evalu-
ation has changed significantly the toxicological profile 
of glyphosate, compared to the previous EU assessment 
(Table 8).
The Acute Reference Dose (ARfD) and Acceptable 
Daily Intake (ADI) represent oral doses that should not be 
exceeded in a single event (or repeated within 24 h) or daily 
in long term exposures, respectively. The Acceptable Oper-
ator Exposure Level (AOEL) represents a systemic daily 
dose that should not be exceeded in non-dietary exposures. 
Figure 1 visualises the current and previous EU toxicologi-
cal reference values for glyphosate, compared with those 
established for the entire group of herbicides assessed in the 
EU. The ranking and percentile within the distribution of 
ca. 150 herbicides assessed in the EU (data extracted from 
the EU pesticides database http://ec.europa.eu/food/plant/
pesticides/eu-pesticides-database/public/?event=homepage
&language=EN) gives an indication of the relative toxicity 
of glyphosate to humans compared to the other herbicides. 
In contrast with previous evaluations, effects produced after 
acute exposures were considered relevant, requiring an 
ARfD and an acute risk assessment (European Food Safety 
Authority 2015b). The human, animal and mechanistic 
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evidence indicates that glyphosate cannot be considered as 
a potent DNA reactive tumour-initiating chemical, and that 
a risk assessment based on threshold toxicological refer-
ence values is scientifically valid (SCOEL 2013). The data 
summarised in Tables 4, 5 and 6 confirms that the proposed 
reference values (Table 8) provide sufficient protection for 
all effects observed in the carcinogenicity and long-term 
toxicity studies, including the trends for tumour induction 
considered as sufficient evidence by IARC.
Glyphosate has a relative low long-term dietary toxic-
ity, being within the 10% of herbicides with higher ADI. 
Regarding short-term dietary exposure, the EU assessment 
proposed an ARfD which ranks glyphosate as slightly more 
toxic (45th percentile) than the average for herbicides. This 
new toxicological profile requires the re-assessment of 
health risks, which had only considered chronic exposure 
until now (Shao-Wen and Chun-Hong 2015). The need for 
personal protective equipment for glyphosate applicators is 
identified in the EFSA Conclusion. The need for an ARfD 
triggers also new considerations regarding the role of spo-
radic AOEL exceedance when addressing the risk of short-
term inhalation and dermal exposures during application, 
including bystander and resident exposure in aerial applica-
tions, which are standard practice outside the EU in forest 
(Rolando et  al. 2013) and for the control of illegal crops 
(Benner et  al. 2016). Exposure estimations for children 
entering the area after application (Solomon et al. 2007) are 
higher than the proposed toxicological threshold.
Regarding residues in food, a comprehensive update 
of the dietary risk assessment will be performed in the 
EU, following the decision on the approval of glypho-
sate, covering all EU uses and the residues expected on 
imported food. Meanwhile, Niemann et  al. (2015) have 
compiled information on human biomonitoring data, 
and concluded that current exposures are well below the 
toxicological references values; exposure of European 
Table 8  Summary of the recent EU toxicological assessment of glyphosate and derivation of reference doses of risk assessment
Relevant endpoints
mg/kg body weight (per day)
Uncertainty factor Reference dose for risk assessment mg/kg 
bw (per day)
Chronic dietary toxicity Rat overall NOAEL: 100
Mice overall NOAEL: 150
Rodent reproductive NOAEL: 300
Rat neurotoxicity NOAEL: 617
Dog short-term NOAEL: 300
Critical endpoint: Rabbit NOAEL: 50 
(maternal and developmental, also rel-
evant for short-term exposures)
100 Acceptable Daily Intake (ADI): 0.5
Acute dietary toxicity 100 Acute Reference Dose (ARfD): 0.5
Chronic non-dietary toxicity 100 × 5 (accounting for 
20% oral absorption)
Acceptable Operator Exposure Level 
(AOEL): 0.1
Fig. 1  Graphical representa-
tion of the EFSA proposed 
changes in the glyphosate 
toxicological profile expressed 
as the relative toxicity ranking. 
This ranking represents the 
percentile of each glyphosate’s 
Toxicological Reference Value 
within the distribution of 141 
herbicides assessed in the EU 
(data extracted from the EU 
pesticides database. http://
ec.europa.eu/food/plant/pesti-
cides/eu-pesticides-database/
public/?event=activesubstance.
selection&language=EN on 25 
May 2016)
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citizens seems to be lower than that of Americans. To 
complement these estimations, an indicative consumer 
exposure assessment based on EU monitoring data for 
glyphosate residues in food generated by competent 
authorities in the EU Member States is described below. 
The assessment covers over 10,000 samples of different 
types of food analysed for glyphosate residues between 
2012 and 2014 (Fig. 2). Member States focussed the con-
trol activities for glyphosate mainly on crops relevant for 
human consumption, where the presence of glyphosate 
was expected, such as cereals (almost 4000 samples), fol-
lowed by fruits, vegetables, pulses and oilseeds; it should 
be noted that only limited information is available on 
feed products such as soya beans (only nine soya beans 
samples were analysed). Overall glyphosate was detected 
in 6.3% of the samples, mostly in cereals (11.7% of the 
samples analysed contained residues above the Limit 
of Quantification), but also in lentils, linseed and table 
grapes, mostly from outside the EU. The legal limits were 
exceeded in 0.2% of the samples analysed for glyphosate. 
A very conservative risk assessment screening has been 
conducted with the EFSA PRIMO model (European Food 
Safety Authority 2007), using conservative assumptions. 
Table 9 summarises the residue levels measured in food 
items which were identified as main contributors in the 
risk assessment using European food consumption data. 
The data have been extracted from the EU pesticides 
residues monitoring programme (European Food Safety 
Authority 2016). Detailed information is provided in the 
supporting information.
Fig. 2  Summary of EU 
monitoring data on glyphosate 
residues in food (2012–2014)
Table 9  Glyphosate residue 
levels reported for the food 
items contributing with over 
0.1% of the ADI or 2% of 
the ARfD in the European 
consumers’ risk assessment 
(EFSA 2016)
$ The mean value is similar to the Limit of Quantification
Food item Number of samples 
analysed for glyphosate
Percentage of samples 
with residues > LOQ
Maximum level
mg/kg
Mean value
mg/kg
Apples 215 1.9 0.10 0.02$
Barley 188 18.6 8.00 0.24
Beans (dry) 132 11.4% 4.00 0.16
Beans (with pods) 123 0.8% 0.05 0.02$
Lentils (dry) 277 30.3% 19.00 0.59
Oranges 192 0.5% 0.10 0.03$
Peas (dry) 41 37.7% 6.39 0.59
Peas (with pods) 38 7.9% 1.40 0.13
Peas (without pods) 22 0% 0.10 0.04$
Potatoes 88 0% 0.10 0.02$
Rye 557 4.1% 3.40 0.13
Wheat 2318 13.2% 4.00 0.14
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The acute risk assessment used the maximum reported 
result. The chronic risk assessment used mean residue 
concentrations, assuming that residues below the Limit 
of Quantification (LOQ) actually occurred in concentra-
tions equivalent to the LOQ; considering that over 94% 
of the samples analysed did not contain residues above 
the LOQ, this assumption contributes to the conservatism 
of the estimated exposure. The chronic exposure was well 
below the ADI (0.5% for unprocessed products and 0.6% 
of the ADI when processed foods are included). In the 
acute risk assessment, the highest exposure was calcu-
lated for lentils (23.4% of the ARfD), followed by beans 
(14.6%) and wheat (11.6%). Pending on the on-going 
EFSA assessment, these estimations further support the 
conclusion that glyphosate residues in food do not repre-
sent a public health concern for European citizens.
Conclusions
The following main factors should be considered when 
explaining the differences between IARC and the EU 
evaluations: the evidence and information sources, the 
methodology and the overall aim. The comparison is 
summarised in Table 10.
Evidence in humans
The same epidemiological studies were used in both 
assessments; all studies focussed on farmers exposed to 
formulations. For pesticides, the regulatory dossier may 
include information on medical surveillance and epi-
demiological studies on manufacturing plant personnel 
directly exposed to the active substance; but this was not 
the case for glyphosate. The key IARC role in compiling 
and evaluating human evidence is well proven, and the 
EU assessment was updated to consider recent publica-
tions included in the IARC monograph. The same weak 
evidence in humans for the carcinogenicity of glyphosate 
was interpreted differently by IARC and EFSA. IARC 
considered the association between exposure to glypho-
sate and non-Hodgkin lymphoma as “limited evidence in 
humans”; while in the EU assessment, most experts con-
sidered the evidence as “very limited” and insufficient for 
triggering the classification. The difference in the inter-
pretation between IARC and the EU is mainly related 
to the fact that IARC is because IARC considered that 
glyphosate is carcinogenic in animals, and concluded that 
strong evidence for two mechanisms, genotoxicity and 
oxidative stress, supported the plausibility of the weak 
association in humans.
Evidence on carcinogenicity in experimental animal 
models
Regarding animal carcinogenicity, three main aspects 
should be considered for understanding the different con-
clusions from IARC and EFSA. Lack of consistency among 
studies on the same species and strain at equivalent doses 
supported the conclusion of chance results in the EU 
evaluation. IARC, however, could not use some studies 
included in the EU evaluation, since the EU assessment 
was on-going and only a draft was available at the time 
of the IARC Working Group meeting, limiting the capac-
ity for checking consistency among studies. Second, the 
lack of consistency between sexes; according to the UN-
GHS criteria, a plausible sex-related mechanism should be 
investigated in these cases, and was not identified in the EU 
assessment. No specific guidance is provided in the IARC 
evaluation and no indication is provided in the monograph. 
Third, the role of secondary effects observed at doses with 
excessive toxicity. For regulatory assessments, when classi-
fication is linked to labelling and risk management options, 
secondary effects due to excessive doses are excluded 
as the assessment focuses on the intrinsic capacity of the 
chemical to induce tumours at lower, less toxic doses. This 
element is not described in the IARC methodology, and the 
IARC Working Group considered as positive trends those 
triggered by tumour incidences at doses with demonstrated 
excessive toxicity. Regulatory assessments have access 
to full study reports; for IARC, unpublished industry-
sponsored studies are secondary information sources, and 
their use is limited to the study summaries from previous 
assessments published by other agencies. Despite not hav-
ing access to the original study reports, the IARC Working 
Group was able to run new statistical analyses, although 
its capacity for verifying details relevant for assessing 
the biological relevance was limited by the level of detail 
provided in the reports published by the regulatory agen-
cies. The comparison with the WHO expert group JMPR 
assessments for glyphosate, conducted in 2004 and 2016, 
is informative regarding the value of granting the experts 
access to the full study reports.
Evidence on genotoxicity and other mechanisms 
of carcinogenicity
Regarding sources of mechanistic information, genotox-
icity/mutagenicity should be discussed independently of 
other possible mechanisms. As observed for glyphosate, 
both industry-sponsored and scientific publications offer 
relevant information on the genotoxicity potential of pes-
ticides that has raised interest among the scientific commu-
nity. On one hand, IARC included one industry-sponsored 
study reported by the US-EPA but not those reported by 
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JMPR (JMPR 2006); on the other hand, IARC reviewed 
effects observed in non-mammalian systems, which were 
considered of limited relevance for the assessment of car-
cinogenicity in humans in the regulatory assessment. IARC 
also assessed glyphosate-based formulations.
An important difference among IARC and regulatory 
assessment is the identification of a non-threshold geno-
toxic mode of action for carcinogenicity. This is not part of 
the IARC evaluation, while for regulatory assessment this 
is a key element triggering the risk assessment methodol-
ogy. The IARC monograph used genotoxicity and oxida-
tive stress as supporting mechanistic evidence; according 
to IARC principles, no indication is provided regarding 
threshold or non-threshold modes of action. The IARC 
allocation in group 2A may suggest that for the IARC 
Working Group the evidence on genotoxicity was insuffi-
cient for considering glyphosate as a potent DNA reactive 
non-threshold genotoxic human carcinogen. In fact, all oral 
studies, even at very high doses, are negative and the only 
in vivo mammalian positive evidence was for intraperito-
neal studies at very high doses at which (cyto)toxicity is 
expected. This is again linked to the consideration of sec-
ondary effects due to severe systemic toxicity described 
above for the animal studies, which should be excluded 
for the classification of genotoxicity and carcinogenicity 
according to the UN-GHS criteria.
Other mechanistic studies should be discussed in con-
nection with the methodological approach. With the excep-
tion of genotoxicity, mechanistic data on the mode of 
action are used in the regulatory context for assessing the 
relevance for humans, and are mostly used to downgrade 
the classification (Boobis et al. 2006; Clewell 2005; Meek 
et  al. 2014a). Mechanistic data can be pivotal in IARC 
evaluations with inconclusive evidence in humans (Cogli-
ano et al. 2008; Lauby-Secretan et al. 2016); and IARC has 
used mechanistic data for upgrading 52 agents and down-
grading 8 agents (Cogliano et al. 2008). The recent review 
of the IARC approach for assessing mechanistic informa-
tion may further change this picture. Strong evidence on 
non-genotoxic mechanisms is included in the recent IARC 
assessments for lindane, DDT and 2,4-D (Loomis et  al. 
2015). Moreover, mechanistic information is essential in 
the assessment of causality versus chance and bias.
To summarise, definitions for limited and sufficient evi-
dence in humans and animals are identical for IARC and 
the UN-GHS; however, differences in criteria and meth-
odological considerations for weighing and assessing the 
evidence can lead to divergent interpretations between the 
IARC assessment and regulatory evaluations following the 
UN-GHS criteria, even when based on the same evidence.
The differences between IARC and regulatory assess-
ments are related not only to parallel historical devel-
opments, but to the different overall scope. IARC 
classifications represent a first step, alerting on the car-
cinogenicity potential of a broad range of agents; scien-
tific regulatory assessments are connected to specific risk 
management recommendations, such as labelling, pack-
aging requirements, use restrictions, etc., and produce the 
basis to be used in the risk assessment. In this different 
context, the focus and role of conservativeness is very 
different. While IARC assessments are not connected to 
risk management decisions, and are based exclusively on 
published information, without access to the full study 
reports for regulated products, regulatory assessments 
may identify data gaps and request additional studies to 
confirm or exclude potential concerns identified during 
their evaluation.
Human health safety is a critical issue for understand-
ing the consequences of scientific divergences regarding 
the carcinogenicity classification of glyphosate. Regulatory 
assessments cover all relevant effects, not only carcino-
genicity. Effects other than tumour induction were respon-
sible for setting the NOAELs of the long-term toxicity–car-
cinogenicity studies, and the toxicological reference values 
were established from critical effects observed at lower 
dose levels in other studies. From a health assessment per-
spective, the IARC-EFSA scientific divergence is at lower 
dose levels that are in reality of limited, if any, relevance. 
The toxicological reference values proposed by EFSA pro-
vide a margin of protection of about four orders of mag-
nitude for the trends in tumour induction and genotoxic 
damage at toxic levels reported by IARC. Those effects are 
expected only in concomitance with other signs of toxic-
ity and at exposure levels orders of magnitude higher than 
the toxicological reference values recommended by EFSA. 
Risk assessments based on human biomonitoring and mon-
itoring of levels of glyphosate residues in food have not 
identified concerns for consumers, and a full consumers’ 
risk assessment of all EU uses is on-going.
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